KACTUS is a company founded in March 2018 that specializes in expertly designing and manufacturing recombinant proteins and enzymes, offering over 3000 catalog and custom production options. Their mission is to deliver quality recombinant proteins and GMP enzymes with a commitment to reliability, speed, and innovation, focusing on relevant solutions in key research areas such as MHC monomers & tetramers, antibody target proteins, gene editing reagents, RNA synthesis enzymes, cell therapy proteins, VLPs & Nanodiscs, and soluble TCR expression. KACTUS utilizes a proprietary Structure Aided Multiplex Screening (SAMS™) Technology Platform, which allows them to tackle difficult-to-express proteins like full-length GPCR and Claudin 18.2, ensuring consistent bioactivity, stability, and verified product quality. They also emphasize sustainability through recyclable packaging and offer extensive customer support and fast shipping.